ACT files IND software to initiate Phase I/II study for Dry out AMD Advanced Cell Technology, Inc Click to see more . Dry AMD afflicts more than 30 million people worldwide reportedly, including an estimated13-15 million Americans. Approximately 10 percent of people 66 to 74 years will have results of macular degeneration, and this prevalence increases to 30 percent in sufferers 75 to 85 years. Dry out AMD takes place when the light-sensitive cells in the macula slowly break down, gradually blurring central eyesight in the affected eyesight.
Take action responds to FDA queries in Phase I/II study using ES cell derived retinal cells to treat SMD Advanced Cellular Technology, Inc. announced today that it has submitted documentation and a complete response to substantively address the issues raised by the united states Food and Drug Administration in connection with the Company’s plans to initiate a Phase I/II multicenter research using embryonic stem cell derived retinal cells to take care of sufferers with Stargardt’s Macular Dystrophy . In 2009 November, ACT filed an Investigational New Drug Application to commence treating patients. ACT believes the design of its item and the choice of SMD, from a safety standpoint, represents a perfect cellular product to get early knowledge and knowledge about ES cell safety.